S175
Brachytherapy - Urology
ESTRO 2026
risk, high risk and very high risk groups was 100%, 82% & 84% and 82%, 67% & 72% respectively, 5 and 10 year OS for intermediate risk, high risk and very high risk groups was 86%, 79% & 90% and 66%, 57% & 74% respectively. Five and 10 year BFS for BED <270 was 80% and 59% respectively, for BED >270 was 94 % and 82% respectively. (p-0.011). 5 and ten year OS for BED <270 was 77% and 46% and for BED >270 was 88 % and 71% respectively, (p-0.025). At median follow up of 113.17 months grade 3 GI and GU toxicity was 1 (1%) and 8 (7.4%) respectively. Conclusion: Conclusions: Combined EBRT and HDR-BT yield significantly better BFS without significance difference in OS at five and 10 years. Long term grade 3 GI toxicity was negligible, grade 3 GU toxicity was comparable. BED of more than 270 yielded significantly higher BFS and OS when compared to BED of less than 270. Keywords: brachytherapy, prostate cancer, HDR boost References: I-Chow Hsu, MD* et al, Int J Radiat Oncol Biol Phys . 2021 July 01;110(3): 700–707.Peter J. Hoskin et al Radiotherapy and Oncology 154 (2021) 214–219Daniel Lam Cham Kee et al, Cancer Treat Rev. 2018 Nov:70:265-271.Alvaro A Martinez et al, Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):363-70Galalae RM at al Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1048- 55. Proffered Paper 4607 Comparative Effectiveness of HDR Brachytherapy versus SBRT for Localized Prostate Cancer: A Propensity Score Matched Study Mariana Borras-Osorio 1 , Federico Mastroleo 1,2 , Yuliia Lozko 1 , Sarah Peterson 1 , Mohammad Javad Namazi 1 , Jonathan Moonen 1 , Brian Davis 1 , Brad Stish 1 , Richard Choo 1 , Pisansky Thomas 1 , Jessica Wilson 1 , Mark Waddle 1 1 Department of Radiation Oncology, Mayo Clinic, Rochester, USA. 2 Department of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy Purpose/Objective: Stereotactic body radiotherapy (SBRT) and high-dose- rate brachytherapy (HDR-BT) are well- established ultrahypofractionated radiotherapy modalities, widely used for localized prostate cancer (PCa) treatment. Currently, direct comparison of both modalities is limited and heterogeneous, mainly focused on dosimetric or quality-of-life analysis. This study aims to compare oncologic outcomes of HDR- BTversus SBRT in a retrospective cohort of localized PCa.
feasible and safe option in selected patients with biochemical recurrence of prostate cancer. The observed local control and low acute toxicity rates support its role as an effective modality. Longer follow-up and prospective studies are warranted to refine patient selection and optimize treatment protocols. Keywords: Prostate cancer, Biochemical recurrence, Toxicity Long term results of combined external beam radiotherapy and High dose rate brachytherapy boost in localized and locally advanced prostate cancer vivek j anand 1 , Sudesh Deshpande 1 , Suresh Naidu 2 , Vinay Babu 3 , Ritika Harjani Hinduja 1 , Kannan Venkatesan 1 1 Radiation Oncology, P D Hinduja Hospital & MRC, Mumbai, India. 2 Radiation Oncology, P D Hinduja Hospital & MRC, mumbai, India. 3 p D Hinduja Hospital & MRC, P D Hinduja Hospital & MRC, mumbai, India Digital Poster 4546 Purpose/Objective: To report long term outcome of results of patients with prostate cancer treated with external beam radiation therapy (EBRT) and high dose rate brachytherapy boost (HDR-BT) from a retrospective analysis Material/Methods: 114 patients, adenocarcinoma of prostate were retrospectively studied between 2009–2023. Patients were of favorable intermediate, unfavorable intermediate, high and very high-risk groups, National comprehensive cancer network (NCCN) classification were treated either with short- or long-term androgen deprivation therapy (ADT), EBRT of dose 46 to 60Gy to the pelvis and 8-15Gy either in one or 2 separate fractions of (HDR-BT) to the prostate. Genitourinary (GU) and gastrointestinal (GI) toxicity were recorded according to the RTOG grading criteria. Biochemical failure free survival (BFS) as per phoenix definition and overall survival (OS) was estimated using Kaplan-Meier method. 5 and 10 year BFS and OS were estimated for two groups of biologically equivalent dose (BED) of < 270 and > 270. Results: Median age was 69 years (range 60-84), median follow up was 113.17 months (95% C.I. 93.99,125.39). 22 (19.1%) of patients received 1-12 months of ADT, 90(79%) of patients received 1 to 3 years of ADT. Favorable intermediate, unfavorable intermediate, high and very high-risk group of patients were 2 (1.8%), 7(6.1%), 15 (13%), 66 (58%) and 24 (21%) respectively. Five and 10 year BFS for intermediate
Made with FlippingBook - Share PDF online